# US 2012/0269857 A1 · Analogs of alpha galactosylceramide and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269857 A1
- Document ID: US20120269857A1
- Status: Published application
- Kind: A1
- Application number: 13/464,299
- Filed: 2012-05-04
- Published: 2012-10-25
- Earliest claimed: 2009-05-21
- Assignees: Ludwig Institute for Cancer Research
- Inventors: Vincenzo CERUNDOLO; Richard Schmidt; Gopal Reddy; Rengarajan Balamurugan; Gerd Ritter; Gurdyal Besra; Mariolina Salio; Jonathan Silk
- Web page: https://patentgrep.com/patent/US20120269857A1

## CPC

- C07H 15/00: Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula wherein the variables are defined in the specification, are used in compositions which stimulate T cell responses.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A composition useful as an immune stimulant comprising a compound of formula:
in which
R1 represents a hydrophobic moiety adapted to occupy the C′ channel of human CD1d,
R2 represents a hydrophobic moiety adapted to occupy the A′ channel of human CD1d, such that R1 fills at least at least 30% of the occupied volume of the C′ channel compared to the volume occupied by the terminal nC14H29 of the sphingosine chain of α-galactosylceramide when bound to human CD1d and R2 fills at least 30% of the occupied volume of the A′ channel compared to the volume occupied by the terminal nC25H51 of the acyl chain of α-galactosylceramide when bound to human CD
R3 represents hydrogen or OH,
Ra and Rb each represent hydrogen and in addition, when R3 represents hydrogen, Ra and Rb together may form a single bond,
X represents or —CHA(CHOH)nY or —P(═O)(O−)OCH2(CHOH)mY, in which Y represents CHB1B25
n represents an integer from 1 to 4, m represents 0 or 1,
A represents hydrogen,
one of B1 and B2 represents H, OH or phenyl, and the other represents hydrogen or one of B1 and B2 represents hydroxyl and the other represents phenyl,
in addition, when n represents 4, then A together with one of B1 and B2 together forms a single bond and the other of B1 and B2 represents H, OH or OSO3H
and pharmaceutically acceptable salts thereof, and
a TLR ligand.

### Claim 20 (depends on 19)

The composition of claim 19, wherein said TLR ligand is poly I:C (TLR 3), MPL (TLR 4), imiquimod (TLR 7), R848 (TLR 8), or CpG (TLR 9).

### Claim 21 (depends on 19)

The composition of claim 19, further comprising a tumor antigen.

### Claim 22 (depends on 21)

The composition of claim 21, wherein said tumor antigen is MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11, MAGE-A12, MAGE-A13, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7, GAGE-8, BAGE-1, RAGE-1, LB33/MUM-1, PRAME, NAG, MAGE-Xp2 (MAGE-B2), MAGE-Xp3 (MAGE-B3), MAGE-Xp4 (MAGE-B4), tyrosinase, brain glycogen phosphorylase, Melan-A, MAGE-C1, MAGE-C2, NY-ESO-1, LAGE-1, SSX-1, SSX-2(HOM-MEL-40), SSX-1, SSX-4, SSX-5, SCP-1 or CT-7.

### Claim 23 (depends on 19)

A method for stimulating the immune system of a subject in need thereof, comprising administering an effective amount of the composition of claim 19 to said subject.

### Claim 24 (depends on 23)

The method of claim 23, wherein said subject suffers from cancer.

### Claim 25 (depends on 23)

The method of claim 23, wherein said subject suffers from a viral infection.

### Claim 26 (depends on 23)

The method of claim 23, wherein said subject suffers from a bacterial infection.

### Claim 27 (depends on 19)

The method of claim 19, wherein said subject suffers from asthma, contact dermatitis, psoriasis, or Crohn's disease.

### Claim 28

A kit useful in stimulating the immune system of a subject in need thereof, comprising a separate portion of each of:
(i) a compound of formula:
in which
R1 represents a hydrophobic moiety adapted to occupy the C′ channel of human CD1d,
R2 represents a hydrophobic moiety adapted to occupy the A′ channel of human CD1d, such that R1 fills at least at least 30% of the occupied volume of the C′ channel compared to the volume occupied by the terminal nC14H29 of the sphingosine chain of α-galactosylceramide when bound to human CD1d and R2 fills at least 30% of the occupied volume of the A′ channel compared to the volume occupied by the terminal nC25H51 of the acyl chain of α-galactosylceramide when bound to human CD1d
R3 represents hydrogen or OH,
Ra and Rb each represent hydrogen and in addition, when R3 represents hydrogen, Ra and Rb together may form a single bond,
X represents or —CHA(CHOH)nY or —P(═O)(O−)OCH2(CHOH)mY, in which Y represents CHB1B2,
n represents an integer from 1 to 4, m represents 0 or 1,
A represents hydrogen,
one of B1 and B2 represents H, OH or phenyl, and the other represents hydrogen or one of B1 and B2 represents hydroxyl and the other represents phenyl,
in addition, when n represents 4, then A together with one of B1 and B2 together forms a single bond and the other of B1 and B2 represents H, OH or OSO3H
and pharmaceutically acceptable salts thereof
(ii) a TLR ligand, and
(iii) a container means for holding (i) and (ii).

### Claim 29 (depends on 28)

The kit of claim 28, further comprising a separate portion of a tumor antigen.
